NEJM: How effective is the Pfizer vaccine against the B.1.1.7 and B.1.351 variants of the new coronavirus?

In the face of different new coronavirus mutations, people always ask the same question.

In the face of different new coronavirus mutations, people always ask the same question.

 The answer is yes.

In fact, the real question should not be whether the vaccine works, but how effective is the vaccine? Because even the best vaccines may produce some "breakthrough infections .

In fact, the real question should not be whether the vaccine works, but how effective is the vaccine? Because even the best vaccines may produce some "breakthrough infections .

 The currently known variants of the new crown are B.

In terms of evading immunity , there are two variants that have attracted the most attention: B.

In terms of evading immunity , there are two variants that have attracted the most attention: B.

Recently, a study published on NEJM showed that the effectiveness of Pfizer vaccine against any B.

DOI: 10.

DOI: 10.

Qatar launched a mass immunization campaign using Pfizer vaccine on December 21, 2020.

Starting from January 2021, the emergence of the B.

Research data shows that 14 days or more after the second vaccination of Pfizer, the effectiveness of the vaccine against any recorded B.

Vaccines against serious, severe or fatal diseases caused by infection with any SARS-CoV-2 (the dominant variants of B.

In Qatar, the effectiveness of Pfizer vaccines against infections and diseases

In Qatar, the effectiveness of Pfizer vaccines against infections and diseases

The researchers evaluated the effectiveness of the vaccine through a cohort study design that compares the incidence of infection in the vaccinated population with the incidence of antibody-negative populations in the national cohort.

The researchers evaluated the effectiveness of the vaccine through a cohort study design that compares the incidence of infection in the vaccinated population with the incidence of antibody-negative populations in the national cohort.
The effectiveness of the B.
1.
1.
7 variant is estimated to be 87.
0% (95% CI, 81.
8 to 90.
7), and the effectiveness of the B.
1.
351 variant is 72.
1% (95% CI, 66.
4 to 76.
8).

 Although there are mainly B.
1.
1.
7 and B.
1.
351 variants in the country, the Pfizer vaccine is effective against infections and diseases in the Qatari population.
As of March 31, in Qatar, there have been recorded breakthrough infections in which 6,689 people received one dose of the vaccine and 1,616 people received two doses of the vaccine.
Seven Covid-19 deaths were also recorded among vaccinators: 5 after the first injection and 2 after the second injection.

 Although there are mainly B.
1.
1.
7 and B.
1.
351 variants in the country, the Pfizer vaccine is effective against infections and diseases in the Qatari population.
As of March 31, in Qatar, there have been recorded breakthrough infections in which 6,689 people received one dose of the vaccine and 1,616 people received two doses of the vaccine.
Seven Covid-19 deaths were also recorded among vaccinators: 5 after the first injection and 2 after the second injection.

 

Reference: Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.
1.
1.
7 and B.
1.
351 Variants

Reference: Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.
1.
1.
7 and B.
1.
351 Variants

DOI: 10.
1056/NEJMc2104974

DOI: 10.
1056/NEJMc2104974

 

Leave a message here